Dr. Is In Sessions
Tuesday, May 3, 2022
Lunch Sponsored by Astellas
Understanding long-term Gene and Cell Therapy investment complexities requires a keen awareness of where the science and the markets are headed. That’s why “The Doctor is In” in these updates on the latest GCT technologies. Presented by Mass General Brigham clinicians and innovators from the front lines of care, the sessions are co-hosted by expert analysts from Bank of America and include interactive discussion and Q&A.
Personalizing Cancer Care through RNA Therapies
In this session, Dr. Peruzzi will discuss how RNA for cancer therapy is a versatile of a tool for a protean problem.
Designing for Success: Clinical Trial Approaches for Rare and Ultra-Rare Diseases
In this session, Dr. Vavvas will discuss examples of clinical trials in rare diseases and share insights into how clinical trials should be approached for rare and ultra-rare diseases and how study design is not a one-size fits all.
A New Hope: Cell Therapy and Transplantation for Parkinson’s Disease
In this session, hear experts weigh in on the possibilities of cell therapy development and transplantation for the treatment of Parkinson’s Disease. What does the futures hold and how do we get there?
The Inner Workings of Gene Therapy Manufacturing
In this session, Dr. Nikiforow will provide insights into the world of gene therapy manufacturing and the complexities of scaling, costs and insurance reimbursement.
The Road Ahead: Regulatory Challenges for Gene and Cell Therapy
In this session, Dr. Marks will discuss the ins and outs of regulatory challenges for biological products and therapies in gene and cell therapy and the responsibility to assure safety and effectiveness.
The Mysterious Dark Genome
Dark genome, accounting for ~98.5% of the human genome and containing the non-coding part, offers unprecedented opportunity to look for novel elements that could play a role in human health. This non-coding region consists of repeat elements, enhancers, regulatory sequences and non-coding RNAs. This session will explore this exciting new frontier in biology and how to translate this so called “junk” and previously ignored genome into potential novel therapeutics.